Related Experiment Videos
Poor Prognostic Factors After Gastrostomy in Patients With Amyotrophic Lateral Sclerosis: A Two-Center Retrospective
Tomomi Shijo1,2, Naoki Suzuki2,3, Hitoshi Warita2
1Department of Neurology, Shodo-Kai Southern Tohoku General Hospital, Iwanuma, Miyagi, Japan.
Muscle & Nerve
|August 14, 2026
Summary
Percutaneous endoscopic gastrostomy (PEG) in amyotrophic lateral sclerosis (ALS) patients is linked to worse outcomes with lower forced vital capacity (FVC) and shorter disease duration. Male sex and spinal onset also indicate poorer prognosis after PEG placement.
Area of Science:
- Neurology
- Gastroenterology
- Pulmonology
Background:
- Percutaneous endoscopic gastrostomy (PEG) is a common intervention for dysphagia in amyotrophic lateral sclerosis (ALS).
- However, outcomes post-PEG vary, with some patients experiencing rapid clinical decline.
- Predictors of post-PEG outcomes in ALS patients require further definition.
Purpose of the Study:
- To identify independent prognostic factors influencing outcomes after PEG placement in patients with ALS.
- To define optimal cutoff values for key clinical variables associated with post-PEG prognosis.
Main Methods:
- A retrospective cohort study of 117 ALS patients who underwent PEG prior to tracheostomy.
- Cox proportional hazards modeling and time-dependent receiver operating characteristic analyses were employed.
- Key variables included age, sex, onset site, forced vital capacity (%FVC), disease duration, and body mass index.
Main Results:
- Male sex, spinal onset, %FVC < 63%, and disease duration < 12 months were independently associated with worse post-PEG outcomes.
- Log-rank analyses confirmed significantly shorter survival in patients meeting these criteria.
- These factors highlight critical thresholds for predicting PEG outcomes.
Conclusions:
- Reduced respiratory function (%FVC) and shorter disease duration to PEG are strong indicators of poorer prognosis in ALS patients.
- Male sex is an independent prognostic factor, possibly reflecting biological differences in disease progression.
- Comprehensive clinical assessment is crucial when considering PEG for ALS patients.